AtriCure to Announce Second Quarter 2021 Financial Results

Rhea-AI Summary

AtriCure, Inc. (Nasdaq: ATRC) has announced the release date for its second quarter 2021 financial results, set for August 4, 2021. A conference call will take place at 4:30 p.m. ET on the same day, allowing stakeholders to discuss the results. AtriCure specializes in innovative treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, with its technologies widely used by healthcare professionals. The company aims to improve outcomes for the over 33 million people affected by Afib globally.

Positive

• AtriCure is a leader in Afib treatment technologies, enhancing its market position.
• The Isolator® Synergy™ Ablation System is FDA approved for persistent Afib, indicating strong regulatory support.

Negative

• None.

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release second quarter 2021 financial results on Wednesday, August 4, 2021.

AtriCure will host a conference call at 4:30 p.m. Eastern Time on Wednesday, August 4, 2021 to discuss its second quarter 2021 financial results. The call may be accessed through an operator by calling (844) 884-9951 for domestic callers and (661) 378-9661 for international callers using conference ID number 8299332. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’s corporate website at ir.atricure.com. A replay of the presentation will be available for 90 days following the presentation.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator^® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip^® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE^® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210707005005/en/

FAQ

When will AtriCure release its second quarter 2021 financial results?

AtriCure will release its second quarter 2021 financial results on August 4, 2021.

What time is AtriCure's conference call for the second quarter results?

The conference call for AtriCure's second quarter results is scheduled for 4:30 p.m. ET on August 4, 2021.

What is AtriCure's stock symbol?

AtriCure's stock symbol is ATRC.

What innovative technologies does AtriCure provide?

AtriCure provides technologies for treating atrial fibrillation (Afib) and managing left atrial appendage (LAA) conditions.

How many people are affected by atrial fibrillation globally?

Atrial fibrillation affects more than 33 million people worldwide.